These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 16911343)

  • 21. The Effect of Antiepileptic Drugs on Cognition: Patient Perceived Cognitive Problems of Topiramate versus Levetiracetam in Clinical Practice.
    Bootsma HP; Aldenkamp AP; Diepman L; Hulsman J; Lambrechts D; Leenen L; Majoie M; Schellekens A; de Krom M
    Epilepsia; 2006; 47 Suppl 2():24-7. PubMed ID: 17105455
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Polygonogram with isobolographic synergy for three-drug combinations of phenobarbital with second-generation antiepileptic drugs in the tonic-clonic seizure model in mice.
    Łuszczki JJ; Podgórska D; Kozińska J; Jankiewicz M; Plewa Z; Kominek M; Żółkowska D; Florek-Łuszczki M
    Pharmacol Rep; 2021 Feb; 73(1):111-121. PubMed ID: 33025394
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison and predictors of rash associated with 15 antiepileptic drugs.
    Arif H; Buchsbaum R; Weintraub D; Koyfman S; Salas-Humara C; Bazil CW; Resor SR; Hirsch LJ
    Neurology; 2007 May; 68(20):1701-9. PubMed ID: 17502552
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An overview of the efficacy and tolerability of new antiepileptic drugs.
    Chadwick DW
    Epilepsia; 1997; 38 Suppl 1():S59-62. PubMed ID: 9092963
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Efficacy and tolerability of topiramate, lamotrigine, and levetiracetam in children with refractory epilepsy].
    Kato T; Nakata M; Ide M; Saito K; Yoshida T; Awaya T; Heike T
    No To Hattatsu; 2015 Sep; 47(5):354-9. PubMed ID: 26502652
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term use of Levetiracetam in patients with severe childhood-onset epilepsy.
    von Stuelpnagel C; Holthausen H; Kluger G
    Eur J Paediatr Neurol; 2007 Nov; 11(6):341-5. PubMed ID: 17442601
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Isobolographic characterization of interactions of levetiracetam with the various antiepileptic drugs in the mouse 6 Hz psychomotor seizure model.
    Wojda E; Wlaz A; Patsalos PN; Luszczki JJ
    Epilepsy Res; 2009 Oct; 86(2-3):163-74. PubMed ID: 19596559
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Current pharmacotherapy of epilepsy in adults].
    Beyenburg S
    Bull Soc Sci Med Grand Duche Luxemb; 2005; (3):263-81. PubMed ID: 17176542
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Three-Year Retention Rates of Levetiracetam, Topiramate, and Oxcarbazepine: A Retrospective Hospital-Based Study.
    Sunwoo JS; Park BS; Ahn SJ; Hwang S; Park CY; Jun JS; Kim DW; Lee ST; Jung KH; Park KI; Chu K; Jung KY; Lee SK
    Clin Neuropharmacol; 2017; 40(2):56-62. PubMed ID: 28118167
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and tolerability of levetiracetam in children younger than 4 years: a retrospective review.
    Perry MS; Benatar M
    Epilepsia; 2007 Jun; 48(6):1123-7. PubMed ID: 17430408
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical application of newer anti-epileptic drugs].
    Terada K; Inoue Y
    Rinsho Shinkeigaku; 2012; 52(11):1088-90. PubMed ID: 23196525
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Risks and benefits of new antiepileptic agents in children].
    Aicardi J
    Rev Neurol; 2000 Aug 16-31; 31(4):376-81. PubMed ID: 11008295
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy.
    Chen B; Choi H; Hirsch LJ; Katz A; Legge A; Buchsbaum R; Detyniecki K
    Epilepsy Behav; 2017 Nov; 76():24-31. PubMed ID: 28931473
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Levetiracetam in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center.
    Bootsma HP; Ricker L; Diepman L; Gehring J; Hulsman J; Lambrechts D; Leenen L; Majoie M; Schellekens A; de Krom M; Aldenkamp AP
    Epilepsy Behav; 2007 Mar; 10(2):296-303. PubMed ID: 17317325
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical predictors in patients with refractory epilepsy exposed to levetiracetam: a single-center study.
    Peltola J; Peltola M; Auvinen A; Keränen T; Liimatainen S; Kharazmi E; Fallah M
    Acta Neurol Scand; 2008 May; 117(5):332-6. PubMed ID: 18081915
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and tolerability of the new antiepileptic drugs, I: Treatment of new-onset epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society.
    French JA; Kanner AM; Bautista J; Abou-Khalil B; Browne T; Harden CL; Theodore WH; Bazil C; Stern J; Schachter SC; Bergen D; Hirtz D; Montouris GD; Nespeca M; Gidal B; Marks WJ; Turk WR; Fischer JH; Bourgeois B; Wilner A; Faught RE; Sachdeo RC; Beydoun A; Glauser TA; ; ; ;
    Epilepsia; 2004 May; 45(5):401-9. PubMed ID: 15101821
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Controversies about the new anti-epileptic drugs].
    Serrano Castro PJ; Sánchez Alvarez JC
    Rev Neurol; 2001 Jan 16-31; 32(2):165-71. PubMed ID: 11299481
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The SKATE study: an open-label community-based study of levetiracetam as add-on therapy for adults with uncontrolled partial epilepsy.
    Steinhoff BJ; Somerville ER; Van Paesschen W; Ryvlin P; Schelstraete I
    Epilepsy Res; 2007 Aug; 76(1):6-14. PubMed ID: 17681453
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New anti-epileptic drugs for the 21st century.
    McCabe PH
    Expert Opin Pharmacother; 2000 May; 1(4):633-74. PubMed ID: 11249508
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New antiepileptic drugs--an overview.
    Sendrowski K; Sobaniec W
    Rocz Akad Med Bialymst; 2005; 50 Suppl 1():96-8. PubMed ID: 16119637
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.